Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) shares are scheduled to reverse split before the market opens on Monday, September 28th. The 1-15 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, September 27th.
Matinas Biopharma Price Performance
Shares of NYSEAMERICAN:MTNB opened at $0.17 on Thursday. Matinas Biopharma has a 1 year low of $0.15 and a 1 year high of $2.02. The firm has a market capitalization of $2.57 million, a PE ratio of -0.15 and a beta of 1.70. The business’s 50 day moving average price is $0.23 and its 200-day moving average price is $0.49.
Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) EPS for the quarter.
About Matinas Biopharma
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company focused on developing oral formulations of medicines that are traditionally administered by injection. The company’s technology platform, known as lipid nanocrystal (LNC) technology, is designed to encapsulate active pharmaceutical ingredients and support their delivery through the gastrointestinal tract.
Matinas’ lead investigational product is MAT2203, an oral formulation of amphotericin B, an antifungal medicine used to treat serious fungal infections.
Read More
- Five stocks we like better than Matinas Biopharma
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
